JAK1-deficient or mutant cell lines show greater tumorigenicity, which has been reported in patients with hepatocellular carcinoma, acute lymphoblastic leukemia, lung cancer, and gastric cancer [14–16]. This evidence concerns the gene JAK1 and lung cancer.